Basis
Asset
Increases NAD+ levels.
- Stage
- Phase 2
- Modality
- Supplement
- Target
- Not known
- 4
- Indications
- 0
- Trials
- 1
- Developer
Indications
4Acute kidney injury
Phase 2, elysiumhealth.com, 10 Oct 2026
Cellular aging
Human trials, elysiumhealth.com, 10 Oct 2026
Menopausal syndrome
Human trials, elysiumhealth.com, 10 Oct 2026
1 more
In the full profile
- Owner and partners1
Every asset’s record: target, stage, trials and the evidence behind it.
Updated 10 Oct 2026, 1 source